Fasting Plasma Caffeine Concentration: A Guide to the Severity of Chronic Liver Disease
- 1 January 1985
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 20 (9) , 1133-1141
- https://doi.org/10.3109/00365528509088884
Abstract
Fasting plasma caffeine concentrations (FPCC) were measured in 86 outpatients being examined for suspected or known liver disease. Seven patients (8%) who avoided caffeine consumption had nonmeasurable FPCC; they were dropped from further consideration. The remaining 79 subjects were divided into 4 diagnostic groups: surgical shunt (n = 11); alcoholic, posthepatitic, or primary biliary cirrhosis (n = 29); miscellaneous liver disease (n = 23); and normal liver (n = 16). FPCC was highest (mean, 17.8 μmol/1) in the shunt group, followed by the cirrhosis (12.3), miscellaneous liver diseases (4.6), and normal liver (2.1) groups. FPCC seemed to reflect severity of functional impairment, further supported by highly significant correlations with quantitative liver function tests, such as aminopyrine breath test (Rs = −0.89; n = 66), indocyanine green disappearance (Rs = −0.85; n = 65), and galactose elimination capacity (Rs = −0.70; n = 75). A careful dietary history showed no significant difference in caffeine consumption among the groups. It is suggested that in regular coffee drinkers FPCC might serve as a simple and convenient guide to the severity of functional impairment in chronic liver disease.Keywords
This publication has 20 references indexed in Scilit:
- High-performance liquid chromatographic determination of dimethylxanthine metabolites of caffeine in human plasmaJournal of Chromatography B: Biomedical Sciences and Applications, 1985
- Evaluation of Caffeine Plasma Levels by an Automated Enzyme Immunoassay (EMIT) in Comparison with a High-Performance Liquid Chromatographic MethodTherapeutic Drug Monitoring, 1984
- Abstracts Submitted to the International Association for the Studv of the LiverHepatology, 1984
- Caffeine: A Model Compound for Measuring Liver FunctionHepatology, 1984
- Portal-systemic spill-over of bile acids: a study of mechanisms using ursodeoxycholic acidEuropean Journal of Clinical Investigation, 1983
- Splanchnic galactose uptake in patients with cirrhosis following single injectionClinical Physiology and Functional Imaging, 1983
- Breath14CO2 after intravenous administration of [14C]aminopyrine in liver diseasesDigestive Diseases and Sciences, 1982
- Drugs as Indicators of Hepatic FunctionHepatology, 1982
- Impaired elimination of caffeine in cirrhosisDigestive Diseases and Sciences, 1980
- Clearance of Antipyrine‐Dependence of Quantitative Liver FunctionEuropean Journal of Clinical Investigation, 1974